Par Pharmaceutical Gains Licensing Rights For Mesothelioma Drug
Par Pharmaceutical Companies Inc.’s of the proprietary products division has stated this week that they have worked at getting the exclusive licensing rights they needed in order to distribute Onconase. Onconase is a drug from Alfacell that is used to treat those who have been diagnosed with malignant and inoperable mesothelioma. Along with the licensing rights they have also acquired the right to commercialize it.